Sanofi places new $1.9B bet even as its last sours; Sam Wak­sal's new biotech ideas; Cell ther­a­py time for Roche; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

As if by some cos­mic kar­ma force, short weeks al­ways have an ex­tra load of big news — as if to com­pen­sate. If you find this re­port help­ful in re­cap­ping it all, please do share it with your col­leagues and friends. Our in­box­es are al­ways open if you have any feed­back or sug­ges­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER